<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title>Official Site for KOKOWA®</title>
    <meta name="keywords" content=""/>
    <meta name="description" content=""/>
    <meta name="applicable-device" content="pc,mobile">
    <link href="../css/bootstrap.css" rel="stylesheet">
    <link href="../css/bxslider.css" rel="stylesheet">
    <link href="../css/style.css" rel="stylesheet">
    <script src="../js/jquery.min.js"></script>
    <script src="../js/bxslider.min.js"></script>
    <script src="../js/common.js"></script>
    <script src="../js/bootstrap.js"></script>
    <!--[if lt IE 9]>
    <script src="../js/html5shiv.min.js"></script>
    <script src="../js/respond.min.js"></script>
    <![endif]-->

</head>

<body>

<header>
    <div class="topBox">
        <div class="borderBottom">
            <div class="container">
                <div class="row">
                    <div class="welcomeBox">KOKOWA<sup>®</sup></div>

                    <div class="languageBox">
                        <a href="../cn/index-cn.html" class="zh">Chinese</a>
                        <a href="../en/index-en.html" class="en">English</a>
                        <a href="../jp/index-jp.html" class="jp">Japanese</a>
                    </div>
                    <div class="topContactBox">
                        <img src="../images/inf.png"/>
                        <a href="kokowaproduct-cautions-cn.html">Information</a>
                        <img src="../images/mail.png"/>
                        <a href="mailto:aa@aa.com">Doctor</a>
                    </div>
                </div>
            </div>
        </div>

    </div>

    <!-- Fixed navbar -->
    <nav class="navbar navbar-default navbar-fixed-top">
        <div class="container">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar"
                        aria-expanded="false" aria-controls="navbar">
                    <span class="sr-only">Toggle navigation</span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
                <a href="index-en.html"><img src="../images/logo1.png" class="logo" alt="welcome~"/></a>

            </div>
            <div id="navbar" class="navbar-collapse collapse">
                <ul class="nav navbar-nav navbar-nav-c">
                    <li class="dropdown">
                        <a href="aboutWT1-en.html">About WT1</a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="aboutWT1-en-whatswt1.html">What's WT1?</a></li>
                            <li><a href="vaccineAdaptedCancer-en.html">Identification of Human WT1 Protein-derived
                                CTL(HLA CLASS I)
                                and HELPER(CLASS II) Epitopes</a></li>
                            <li><a href="principleOfWT1-en.html">The principle of WT1 as a tumor suppressor antigen</a>
                            </li>
                        </ul>
                    </li>

                    <li class="dropdown">
                        <a href="kokowa-en.html">About KOKOWA<sup>®</sup></a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="kokowa-en.html">What's KOKOWA<sup>®</sup></a></li>
                            <li><a href="kokowaproduct-en.html">KOKOWA<sup>®</sup> Product Description</a></li>
                        </ul>
                    </li>
                    <li class="dropdown">
                        <a href="javascript:;">What should we do?</a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="">Talk to your Doctor</a></li>
                        </ul>
                    </li>
                    <li class="dropdown">
                        <a href="javascript:;">Access and support</a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="moreProfessionalQuestion-en.html">More Professional Questions</a></li>
                        </ul>
                    </li>

                </ul>

            </div><!--/.nav-collapse -->
        </div>
    </nav>
</header>

<!-- bxslider -->
<div class="flash">
    <img src="../images/kokowa-wt1-en-1.png" alt=""/>
</div>


<!--div class="page_bg" style="background: url(../images/smal-banner-jp.png) center top no-repeat;">
</div-->

<div class="container threeImgBox">
    <div class="row">
        <div class="index_wt1">
            <h2>The principle of WT1 as a tumor suppressor antigen</h2>
            <ul>
                <li><a target=_blank href="javascript:;">Introduction</a>
                    <a target=_blank href="javascript:;">Principle of Peptide-Based Cancer Vaccine</a>
                    <a target=_blank href="javascript:;">Preparation of WT1 Peptide-Based Cancer Vaccine</a>
                </li>
                <!--<div class="detailContent"></div>-->
                <!--<div class="detailTime">2017/7/13 22:54:35</div>-->
            </ul>
        </div>0

    </div>
</div>

<div class="container" style="border-bottom:1px dashed #000;background:#ffe; filter: Alpha(Opacity=10, Style=0);">
    <div class="col-xs-12 col-sm-4 col-md-5">
        <div class="index_contact">
            <h2 class="left_h2">Introduction</h2>
            <ul class="index_news">
                <img src="../images/cancerwork.jpg" alt="">
            </ul>
        </div>
    </div>

    <div class="col-xs-12 col-sm-8 col-md-7">
        <div class="contents">

            <ul class="index_news">
                <!--h2 class="left_h2"></h2-->
                <p class="content">
                    The immune system evolved to distinguish self and nonself and to effectively protect the individual
                    from microorganisms, many of which cause diseases, and the resulting damage; the immune system also
                    protects us against cancers and toxins, in order to help maintain our normal activities<sup class="contents_sup">1</sup>. Cancer
                    cells are self-cells with aberrant growth potential, acquired as a result of several gene
                    abnormalities <sup class="contents_sup">2</sup>. The idea that the immune system could control cancer growth has been discussed
                    for over a century. “Evading immune destruction” has been recently added in the hallmarks of cancer,
                    proposed by Hanahan and Weinberg in 2011 <sup class="contents_sup">2</sup>. We clinically encounter cancer cells that have escaped
                    from immune surveillance. Recent progress in cancer immunity has been answering questions about how
                    the immune system is involved in the process of cancer formation<sup class="contents_sup">3</sup>, and whether immunotherapy
                    eliminates cancer cells that have undergone immune escape. 
                </p>
                <p class="content">
                The identifi cation of MAGE-A1 in melanoma patients, described as the fi rst cancer antigen by Boon et
                    al. in 1991 <sup class="contents_sup">4</sup>, opened the door to antigen-specifi c cancer immunotherapiesfrom nonspecifi c ones
                    such as immune-adjuvants <sup class="contents_sup">5</sup><sup class="contents_sup">6</sup> and cytokines <sup class="contents_sup">7</sup>.
                    During the next two decades, many cancer antigens
                    have been identifi ed, including WT1, leading to the development of more effective cancer
                    immunotherapies <sup class="contents_sup">8</sup><sup class="contents_sup">9</sup><sup class="contents_sup">10</sup>.
                    Currently, cancer immunotherapyis expected for the fourth most common cancer
                    therapy, behind surgical resection, radiotherapy, and chemotherapies (including molecular target agents).
                </p>
            </ul>
        </div>
    </div>

</div>

<div class="container">
    <div class="row">

        <!-- right -->
        <div class="col-xs-12 col-sm-8 col-md-9" style="float:right">
            <div class="list_box">
                <h2 class="left_h2">Principle of Peptide-Based Cancer Vaccine</h2>
                <div class="contents">
                    <p>
                        In most of cancer immunotherapy , the key process involves exploiting the intrinsic capacity of
                        dendritic cells ( DCs )in vivo or ex vivo in order to induce antigen-specifi c T-cell
                        responses<sup class="contents_sup">13-</sup><sup class="contents_sup">15</sup>. Peptidebased cancer vaccines, which are simple and easily adapted to a
                        variety of cancer patients, are widely used in clinical trials . The principles of peptide-based
                        cancer vaccines, which consist of HLA class I-restricted peptide and immune adjuvant, are as
                        follows (Fig. 1)<sup class="contents_sup">16</sup><sup class="contents_sup">17</sup>.
                    </p>
                    <p>
                        HLA class I-restricted peptides are injected intradermally or subcutaneously along with some immune
                        adjuvant. Peptides bind to the HLA class I molecules on the surface of DCs , or are taken up and
                        presented on the cell surface along with HLA class I molecules by immature DCs . Immune adjuvant
                        injected at the same time stimulates immature DCsin peripheral tissues。
                    </p>
                    <p>
                        These activated DCsmigrate via lymphatics to regional lymph nodes, where they arrive as fully
                        mature DCsthat express both antigen/HLA-molecule complexes and costimulatory molecules necessary
                        to stimulate antigen-specifi c T- lymphocytes .
                    </p>

                    <p>Antigen-specifi c T-lymphocytes, especially CD8 + cytotoxic T-lymphocytes ( CTLs ), are stimulated
                        to proliferate and differentiate by mature DCsand form a clone of effecter cells.
                    </p>
                    <p>
                        Ultimately, antigen-specifi c CTL senter the tumor bed, and kill the targeted cancer cells by
                        inducing apoptosis and releasing specialized cytotoxic granules, such as perforin and granzymes,
                        upon recognition of the antigen on the surfaces of tumor cells.
                    </p>

                    <div>
                        <image src="../images/p8.png" class="contents_image"/>
                        <p class="contents_imageNote">Fig. Mechanism of peptide-based cancer vaccines.</p>
                        <p class="contents_imageNote">
                            Cancer cells express some antigens recognized by the host immune system, and present the
                            peptide derived from this antigen/HLA class I complex on the cell surface. Antigen-specifi
                            c cytotoxic lymphocytes that are elicited by peptide-based cancer vaccines recognize peptide/HLA
                            class I complexes via the T-cell receptor (TCR).</p>
                        <p class="contents_imageNote">
                            <p class="contents_sup">1</p>、Injection of cancer antigen and immune adjuvant  
                        </p>
                        <p class="contents_imageNote">
                        <p class="contents_sup">2</p>、Migration to lymph node and presentation of cancer antigen to T-cells; antigen-specifi c
                        cytotoxic T-lymphocytes ( CTLs )  
                        </p>
                        <p class="contents_imageNote">
                        <p class="contents_sup">3</p>、Proliferation and differentiation of T-lymphocytes 
                        </p>
                        <p class="contents_imageNote">
                        <p class="contents_sup">4</p>、Cytotoxicity mediated by antigen-specifi c CTLs 
                        </p>
                    </div>
                </div>
            </div>
            <div class="list_box">

                <h2 class="left_h2">Preparation of WT1 Peptide-Based Cancer Vaccine</h2>
                <div class="contents">
                    <p>
                        Peptide-based vaccinesgenerally consist of peptides and immune adjuvants. Peptides can be further
                        divided into two groups: HLArestricted short peptides, and non-HLA-restricted long peptides<sup class="contents_sup">30</sup>.
                        A majority of clinical studies of cancer immunotherapiestargeting WT1 have used HLA-restricted
                        short peptide-based vaccines. 
                    </p>
                    <p>
                        Peptides: HLA-restricted short peptides are used; specifi - cally, HLA-A*24:02-restricted modifi
                        ed 9-mer WT1 235 peptide and/or HLA-A*02:01-restricted 9-mer WT1 126 peptide. The doses of peptide
                        are usually 3 mg/body, although the recommended doses (RD) of the peptides have not been determined
                        in dose- escalation studies<sup class="contents_sup">28</sup><sup class="contents_sup">31</sup>. 
                    </p>
                    <p>
                        Adjuvants: Immune adjuvants are materials that enhance the immune response. Their functions can
                        be broadly divided into two categories: (1) transport medium, by which antigen presenting cells
                        (APCs), including DCs , engulf vaccine antigens effectively; and (2) immune modulator. The latter
                        role is the more important of the two. The activation of DCsthrough the pattern recognition
                        receptors (PRRs), such as Toll-like receptors (TLRs), is the most important process and is crucial
                        for initiating the innate immunity response: such signaling makes immature DCs , whose sole
                        function is to capture microbes and the dead cells, differentiate into mature DCs , which can
                        process and present their antigens to T-lymphocytes in regional lymph nodes <sup class="contents_sup">33</sup><sup class="contents_sup">34</sup><sup class="contents_sup">35</sup>. Immune
                        adjuvants work like pathogenassociated molecular patterns (PAMPs) and damage-associated molecular
                        pattern (DAMPs) to activate DCs .
                    </p>
                    <p>
                        Products: We describe the vaccine product frequently used in our clinical setting as follows:
                        3 mg of WT1 peptide is dissolved in a small volume of dimethyl sulfoxide (DMSO), and then the
                        peptide solution is diluted to 400 μl with 5 % glucose. Ultimately, the mixture is emulsifi ed
                        with an equal weight of Montanide ISA51 adjuvant <sup class="contents_sup">28</sup>.
                    </p>
                </div>
            </div>
        </div>

        <!-- left -->
        <div class="col-xs-12 col-sm-4 col-md-3">
            <div class="left_news">
                <h2 class="left_h2">References</h2>
                <ul class="index_news">
                    <li>
                        <a href="https://www.sciencedirect.com/science/article/pii/009286749090601A"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">1</sup>. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome
                            11 Wilms tumor locus.
                        </a>
                        <span class='news_time'> Cell 1990;60:509–20.</span>
                        <span class='news_time'>Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al.</span>
                    </li>
                    <li>
                        <a href="https://www.nature.com/articles/343774a0"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">2</sup>. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome
                            jumping.
                        </a>
                        <span class='news_time'>Nature 1990;343:774– 8.</span>
                        <span class='news_time'>Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP. </span>
                    </li>
                    <li>
                        <a href="https://link.springer.com/article/10.1007/BF02981935"
                           title="Wilms’ tumor gene WT1: its oncogenic function and clinical application.">
                            <sup class="contents_sup">3</sup>. Wilms’ tumor gene WT1: its oncogenic function and clinical application.
                        </a>
                        <span class='news_time'>Int J Hematol 2001;73:177– 87.</span>
                        <span class='news_time'>Sugiyama H. </span>
                    </li>
                    <li>
                        <a href="https://mcb.asm.org/content/11/3/1707.short"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">4</sup>. Isolation, characterization, and expression of the murine Wilms tumor gene (WT1) during
                            kidney development.
                        </a>
                        <span class='news_time'>Mol Cell Biol 1991;11:1707– 12.</span>
                        <span class='news_time'>Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. </span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/8401592"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">5</sup>. The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a
                            human mesothelioma.
                        </a>
                        <span class='news_time'>Nature Genet 1993;4:415–20.</span>
                        <span class='news_time'>Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, et al. </span>
                    </li>
                    <li>
                        <a href="http://cancerres.aacrjournals.org/content/59/7_Supplement/1747s.short"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">6</sup>. Multiple roles for the Wilms’ tumor suppressor, WT1.
                        </a>
                        <span class='news_time'>Cancer Res 1999;59(Suppl 7):1747– 1750s; discussion 1751s.</span>
                        <span class='news_time'>Davies R, Moore A, Schedl A, Bratt E, Miyahawa K, Ladomery M, et al. </span>
                    </li>
                    <li>
                        <a href="http://dev.biologists.org/content/126/9/1845"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">7</sup>. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal
                            gland and throughout nephrogenesis.
                        </a>
                        <span class='news_time'>Development 1999;126:1845–57.</span>
                        <span class='news_time'>Moore AW, Mclnnes L, Kreidberg J, Hastie ND, Schedl A.  </span>
                    </li>
                    <li>
                        <a href="https://europepmc.org/abstract/med/1317488"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">8</sup>. Expression of the Wilms tumor gene (WT1) in human leukemias.
                        </a>
                        <span class='news_time'>Leukemia 1992;6:405 –9.</span>
                        <span class='news_time'>Miwa H, Beran M, Aunders GF.  </span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/8321047"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">9</sup>. Expression of the Candidate Wilms tumor gene, WT1, in human leukemia cells.
                        </a>
                        <span class='news_time'>Leukemia 1993;7:970 –7.</span>
                        <span class='news_time'>Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. </span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/7949179"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">10</sup>. WT1 as new prognostic factor a new marker for the detection of minimal residual disease
                            in acute leukemia.
                        </a>
                        <span class='news_time'>Blood 1994;84:3071–9.</span>
                        <span class='news_time'>Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. </span>
                    </li>
                    <li>
                        <a href="http://www.bloodjournal.org/content/bloodjournal/90/3/1217.full.pdf?sso-checked=true"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">11</sup>. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated
                            with a worse long-term outcome.
                        </a>
                        <span class='news_time'>Blood 1997;90:1217– 25.</span>
                        <span class='news_time'>Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, et al. </span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/7808002"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">12</sup>. The expression of the Wilms tumor gene in acute myelocytic leukemias as a possible
                            marker for leukemic blast cells.
                        </a>
                        <span class='news_time'>Leukemia 1994;8:2138–43.</span>
                        <span class='news_time'>Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L.</span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/7596170"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">13</sup>. Presence of Wilms tumor gene (wt1) transcripts and the WT1 nuclear protein in the
                            majority of human acute leukemias.
                        </a>
                        <span class='news_time'>Leukemia 1995;9:1060–7.</span>
                        <span class='news_time'>Menssen HD, Renkl H-J, Rodeck U, Maurer J, Notter M, Schwartz S, et al.</span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19970304)70:5%3C518::AID-IJC5%3E3.0.CO;2-0"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">14</sup>. Detection by monoclonal antibodies of the Wilms’ tumor (WT1) nuclear protein in patients
                            with acute leukemia.
                        </a>
                        <span class='news_time'>Int J Cancer 1997;70:518–23.</span>
                        <span class='news_time'>Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E.</span>
                    </li>
                    <li>
                        <a href="https://www.nature.com/articles/2402675"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">15</sup>. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful
                            tool for monitoring minimal residual disease in acute leukemia patients.
                        </a>
                        <span class='news_time'>Leukemia 2002;16:2115– 21.</span>
                        <span class='news_time'>Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al.</span>
                    </li>
                    <li>
                        <a href="https://www.sciencedirect.com/science/article/pii/S1083879112000511"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">16</sup>. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase
                            chain reaction for Wilms tumor gene (WT1).
                        </a>
                        <span class='news_time'>Int J Hematol 2003;78:349– 56.</span>
                        <span class='news_time'>Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N, et al. </span>
                    </li>
                    <li>
                        <a href="http://www.bloodjournal.org/content/101/5/1698/tab-figures-only"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">17</sup>. The usefulness of monitoring WT1 gene transcripts for the prediction and management of
                            relapse following allogeneic stem cell transplantation in acute type leukemia.
                        </a>
                        <span class='news_time'>Blood 2003;101:1698–704.</span>
                        <span class='news_time'>Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, et al. </span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.11623"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">18</sup>. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia
                            for the development of specific immunotherapies.
                        </a>
                        <span class='news_time'>Int J Cancer 2004;108:704– 11.</span>
                        <span class='news_time'>Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, et al.</span>
                    </li>
                    <li>
                        <a href="https://www.nature.com/articles/2401341.pdf?origin=ppub"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">19</sup>.The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of
                            myelodysplastic syndromes.
                        </a>
                        <span class='news_time'>Leukemia 1999;13:393–9.</span>
                        <span class='news_time'>Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki J-H, Iwama H, Inoue K, et al.  </span>
                    </li>
                    <li>
                        <a href="https://www.nature.com/articles/srep08924"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">20</sup>.Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell
                            growth.
                        </a>
                        <span class='news_time'>Jpn J Cancer Res 1999;90:194– 204.</span>
                        <span class='news_time'>Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al.  </span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1349-7006.2004.tb02188.x"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">21</sup>.Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors.
                        </a>
                        <span class='news_time'>Cancer Sci 2004;95:822– 7.</span>
                        <span class='news_time'>Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, et al. </span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1349-7006.2003.tb01477.x"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">22</sup>.Overexpression of the Wilms’ tumor gene WT1 in head and neck squamous cell carcinoma.
                        </a>
                        <span class='news_time'>Cancer Sci 2003;94:523– 9.</span>
                        <span class='news_time'>Oji Y, Inohara H, Nakazawa M, Nakano Y, Akahani S, Nakatusuka S, et al.</span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1349-7006.2003.tb01490.x"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">23</sup>.Overexpression of the Wilms’ tumor gene WT1 in primary thyroid cancer.
                        </a>
                        <span class='news_time'>Cancer Sci 2003;94:606–11.</span>
                        <span class='news_time'>Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatuska S, et al.</span>
                    </li>
                    <li>
                        <a href="http://ar.iiarjournals.org/content/24/5B/3103.short"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">24</sup>.Overexpression of the Wilms’ tumor gene WT1 in esophageal cancer.
                        </a>
                        <span class='news_time'>Anticancer Res 2004;24:3103– 8.</span>
                        <span class='news_time'>Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, et al. </span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.10476"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">25</sup>.Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers.
                        </a>
                        <span class='news_time'>Int J Cancer 2002;100:297– 303.</span>
                        <span class='news_time'>Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, et al.</span>
                    </li>
                    <li>
                        <a href="http://cancerres.aacrjournals.org/content/61/3/921"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">26</sup>.Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite
                            tumor-specific promoter methylation.
                        </a>
                        <span class='news_time'>Cancer Res 2001;61:921– 5.</span>
                        <span class='news_time'>Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, et al.</span>
                    </li>
                    <li>
                        <a href="https://pdfs.semanticscholar.org/d8be/6f4896132680fc8761b686ca599860c14c5d.pdf"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">27</sup>.High expression of Wilms’ tumor suppressor gene (WT1) predicts poor prognosis in breast
                            cancer patients.
                        </a>
                        <span class='news_time'>Clin Cancer Res 2002;8:1167–71.</span>
                        <span class='news_time'>Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, et al. </span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/15245594"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">28</sup>.Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma.
                        </a>
                        <span class='news_time'>Cancer Sci 2004;95:583–7.</span>
                        <span class='news_time'>Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, et al. </span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2003.tb01507.x"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">29</sup>.Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma.
                        </a>
                        <span class='news_time'>Cancer Sci 2003;94:712–7.</span>
                        <span class='news_time'>Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, et al. </span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2003.tb01432.x"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">30</sup>.Overexpression of the Wilms’ tumor gene WT1 in human bone soft-tissue sarcomas.
                        </a>
                        <span class='news_time'>Cancer Sci 2003;94:271– 6.</span>
                        <span class='news_time'>Ueda T, Oji Y, Naka N, Nakano Y, Takahashi E, Koga S, et al.</span>
                    </li>
                    <li>
                        <a href="https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2004.tb02188.x"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">31</sup>.Absence of mutations in the Wilms’ tumor gene WT1 in primary breast cancer.
                        </a>
                        <span class='news_time'>Jpn J Clin Oncol 2004;34:74 –7.</span>
                        <span class='news_time'>Oji Y, Miyoshi Y, Kiyotoh E, Koga S, Nakano Y, Ando A, et al.</span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/15004653"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">32</sup>.Absence of mutations in the Wilms’ tumor gene wt1 in de novo non-small cell lung cancers.
                        </a>
                        <span class='news_time'>Neoplasma 2004;51:17 –20.</span>
                        <span class='news_time'>Oji Y, Miyoshi S, Takahashi E, Koga S, Nakano Y, Shintani Y, et al.</span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/15004653"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">32</sup>.Absence of mutations in the Wilms’ tumor gene wt1 in de novo non-small cell lung cancers.
                        </a>
                        <span class='news_time'>Neoplasma 2004;51:17 –20.</span>
                        <span class='news_time'>Oji Y, Miyoshi S, Takahashi E, Koga S, Nakano Y, Shintani Y, et al.</span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/15004653"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">51</sup>.没有.
                        </a>
                        <span class='news_time'>Neoplasma 2004;51:17 –20.</span>
                        <span class='news_time'>Oji Y, Miyoshi S, Takahashi E, Koga S, Nakano Y, Shintani Y, et al.</span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/15004653"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">52</sup>.没有.
                        </a>
                        <span class='news_time'>Neoplasma 2004;51:17 –20.</span>
                        <span class='news_time'>Oji Y, Miyoshi S, Takahashi E, Koga S, Nakano Y, Shintani Y, et al.</span>
                    </li>
                    <li>
                        <a href="http://www.bloodjournal.org/content/96/4/1480?sso-checked=true"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">53</sup>.Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.
                        </a>
                        <span class='news_time'>Blood 2000;96:1480 –9. </span>
                        <span class='news_time'>Gaiger A, Reese V, Disis ML, Cheever MA. </span>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pubmed/12792492"
                           title="Radio-detoxified endotoxin activates natural immunity: a review">
                            <sup class="contents_sup">54</sup>.Human cytotoxic T lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
                        </a>
                        <span class='news_time'>Transplantation 2003;75:1429 –36. </span>
                        <span class='news_time'>Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM, et al. </span>
                    </li>

                </ul>
            </div>
        </div>

    </div>
</div>

<footer>
    <div class="copyright">
        <p>
            <a href="faq-en.html" target="_blank">&nbsp;&nbsp;FAQ&nbsp;&nbsp;</a> |
            <a href="moreProfessionalQuestion-en.html" target="_blank">&nbsp;&nbsp;More Professional Questions&nbsp;&nbsp;</a> |
            <a href="sitemap-en.html" target="_blank">&nbsp;&nbsp;Site Map</a>
        </p>
        <p>CopyRight© 2018 All Right Reserved KOKOWA<sup>®</sup> & Japan Cancer Institute Corporation &nbsp;
        </p>
    </div>

</footer>

</body>
</html>
